title: A retrospective review and observational study of outcomes and safety of bimatoprost ophthalmic solution 0.03% for treating eyelash hypotrichosis.
abstract: BACKGROUND
  The efficacy and safety of bimatoprost ophthalmic solution 0.03% for treating hypotrichosis were shown in a randomized controlled trial and in an open-label study. To date, no data on real-world experience have been published.
  
  
  OBJECTIVE
  To evaluate long-term patient satisfaction, usage patterns, and safety of bimatoprost 0.03% in clinical practice.
  
  
  METHODS
  In this retrospective chart review with a cross-sectional design, adult patients exposed to bimatoprost 0.03% for at least 12 months were randomly sampled from 16 investigational sites. Charts were reviewed for medication usage characteristics and adverse events (AEs). At a study visit, questionnaires eliciting patient-reported outcomes were administered and spontaneously reported AEs were tabulated.
  
  
  RESULTS
  Analysis included 585 subjects with a mean (SD) treatment duration of 19.3 (4.3) months. Patient satisfaction with bimatoprost 0.03% was 92.5%; on average, approximately 3 applications per week maintained benefits. Overall, 27.4% of patients spontaneously recalled experiencing AEs while on treatment; however, patient charts showed that only 4 AEs were documented. No instances of iris hyperpigmentation occurred. No serious or severe AEs were noted.
  
  
  CONCLUSIONS
  Treatment with bimatoprost 0.03% for at least 12 months is safe, and long-term use is associated with a high degree of satisfaction.
authors.affiliation: *Medical Associates Inc., Newport Beach, California; †Private Practice, Boca Raton, Florida; ‡Department of Dermatology, School of Medicine, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina; §Aesthetic Solutions, Chapel Hill, North Carolina; ‖Allergan, Inc., Irvine, California; ¶SCI Scientific Communications and Information, Parsippany, New Jersey.
authors.forename: Steven G
authors.initials: SG
authors.lastname: Yoelin
authors.forename: Steven
authors.initials: S
authors.lastname: Fagien
authors.forename: Sue Ellen
authors.initials: SE
authors.lastname: Cox
authors.forename: Paula G
authors.initials: PG
authors.lastname: Davis
authors.forename: Antoinette
authors.initials: A
authors.lastname: Campo
authors.forename: Carrie A
authors.initials: CA
authors.lastname: Caulkins
authors.forename: Conor J
authors.initials: CJ
authors.lastname: Gallagher
mesh_terms: D000328:Adult; D000577:Amides / Q000009:adverse effects / Q000627:therapeutic use*; D000069580:Bimatoprost; D003008:Cloprostenol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D004890:Erythema / Q000139:chemically induced; D005140:Eyelashes; D005141:Eyelid Diseases / Q000139:chemically induced; D005260:Female; D006801:Humans; D007039:Hypotrichosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000009:adverse effects / Q000627:therapeutic use*; D017060:Patient Satisfaction; D010859:Pigmentation Disorders / Q000139:chemically induced; D011537:Pruritus / Q000139:chemically induced; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000577:Amides; D009883:Ophthalmic Solutions; D003008:Cloprostenol; D000069580:Bimatoprost